At se på kursen, så var det nok også en rimelig dårlig en af slagsen 
Trenger ikke være kunde for å vite hva som blir sagt.
Skulle tatt seg ut om selskapet hadde sagt noe til denne kundegruppen som de ikke allerede har sagt på siste Q presentasjon.
Det er nok ingenting av nytt på en slik lukket investorpresentasjon hos ett meglerhus.
3 Likes
Nå tuller du vel. Ingen løper til PC og kjøper 10 min etter en presentasjon
7 Likes
Du vet du kan handle fra telefonen? 
1 Like
Kun ind for at sælge 
sorry.
Trodde vi så bunn nå kl. 16?
Aner ikke hvor stort publikum som hadde tilgang til “piratos” presentasjon men det ble ikke reaksjon på handelen så da får vi trøste oss med at dette nok bare var en oppsummering av podkasten og ingen nye innspill. (hadde ikke forventa annet heller )
Ingenting nytt å melde fra dagens presentasjon, noe som selvsagt er helt som det skal være.
Allikevel meget positivt at PCIB blir plukket ut til en litt lengre presentasjon enn den som de skal holde på konferansen. 
12 Likes
Er det ikke 3 sept. de skal presentere?
PARETO Securities’ 11th annual healthcare conference** , Stockholm Sweden, 2-3 September 2020. Virtual company presentation 11:00 – 11:30 CEST on September 3rd.
3 Likes
Da også men de holdt en presentasjon for norske Pareto-kunder i dag.
5 Likes
Mulig de var på harryhandel i dag. Svineaktig billige aksjer over dammen hos hr Musk i dag.
Blir spennende å se i morgen når det har siget inn for noen nye og kapital er fristilt for bio-handel.
3 Likes
I must admit that I like the new catch phrase (ENABLING INTRACELLULAR DELIVERY) better than (UNLOCKING THE POTENTIAL OF INNOVATIVE MEDICINES)
The new slogan is straight to the point and very explicit. Delivery is a problem and pci solves it. It also does more justice to Fimachem, as fimachem is not necessarily delivering “innovative” medicine (chemo) compared to what Vacc and Nac deliver (CPI, mRNA … etc). Seems that this could be the signature of the new CBO. Well done there is usually beauty in simplicity.
50 Likes
4 mnd. igjen av aaret, De to foerste maanedene gikk fort. Hvor lenge maa vi vente paa svar?
5 Likes
tekbot forsinket?
Børsmelding: PCI Biotech announce a research collaboration with DCprime to explore novel cancer vaccination concepts!!
35 Likes
The collaboration builds on preclinical
proof-of-concept results previously presented by DCprime at the 34th Annual Meeting of
the Society for Immunotherapy of Cancer (SITC) in November 2019 and on PCI Biotech
fimaVACC and fimaNAC technologies.
Da er kanskje eksklusivitetsavtale på fimaNAc me AZ ikke lenger aktuelt? Eller forstår jeg dette feil?
1 Like
Jeg mistenker at det aldri har vært aktuelt
2 Likes
Nærmere om DCprime
(Leiden, NL):
The clinical development of DCprime’s therapeutic candidates currently focuses on treating hematological malignancies, such as acute myeloid leukemia and Myelodysplastic syndrome (MDS). Both diseases have a high risk of relapse, even after initial response to chemotherapy. Repeated treatment or a bone marrow transplant are the only means currently available to control or cure these diseases, so there is a dire need to develop additional therapies. We aim to develop a new class of relapse vaccines to address this need by boosting the patients’ immune system to obtain disease control.
Development Status
DCP-001 is currently being evaluated in a multi-center European Phase II trial in Acute Myeloid Leukemia (AML) patients who have responded to treatment with chemotherapy but are not able to undergo bone marrow transplantation. Patients in complete remission but with measurable residual disease (MRD) will be included. Immune responses to DCP-001 vaccination and effects on MRD will be monitored to evaluate the efficacy of this relapse vaccine.
More details on the ADVANCE II study, as well as participating hospitals under the Horizon2020 AML-VACCiN program, can be found at www.amlvaccin.eu or on www.clinicaltrials.gov.
DCP-001 has previously been evaluated in patients with AML in a Phase I clinical study with top-line data having been published in Cancer Immunology, Immunotherapy in mid-2018 and long-term follow-up and survival data presented at ASH 2019. The primary objectives of the study (feasibility and safety) were achieved, with 10 out of the 12 patients completing the vaccination program. Treatment was well-tolerated and generated both cellular and humoral immune responses.
For more information on the Phase 1 trial, please go to www.clinicaltrials.gov.
DCP-001 has been granted Orphan Drug Status in the US and the EU.
6 Likes
Dette gir vel en bekreftelse om at oppkjøp fra AZ er utelukket. I tillegg er det ingen penger inn. Dette var ikke bra…
Dette bekrefter også at samarbeidet med lovende Biontech ikke ble avsluttet pga. AZ sånn som jeg ser det.